Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapyWalter J Urba
Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
J Urol 180:2011-7; discussion 2017-8. 2008
..This phase I-II study evaluated the safety, clinical activity and immunogenicity of an immunotherapy developed from human prostate cancer cell lines (PC-3 and LNCaP) modified to secrete granulocyte-macrophage colony-stimulating factor...
gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cellsEdwin B Walker
Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
Clin Cancer Res 10:668-80. 2004
..The data further support the combined use of tetramer binding and functional assays in correlated ex vivo and IVS settings as a standard for immunomonitoring of cancer vaccine patients...
CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted miceLi Xin Wang
Laboratory of Cancer Immunobiology, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213, USA
Eur J Immunol 40:1375-85. 2010
..Our results demonstrate the lymphopenia-driven proliferation of CD122+CD8+ Treg in reconstituted lymphodepleted mice limited the antitumor efficacy of DC vaccination in conjunction with adoptive transfer of tumor-specific T cells...
- Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide
Sybren L Meijer
Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, 4805 NE Glisan Street, Portland, OR 97213, USA
J Immunother 30:533-43. 2007
....
- Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma
Yiwei Chu
Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213, USA
J Immunother (1997) 29:367-80. 2006
..Thus, augmentation of vaccine induced antitumor immunity in docetaxel-treated mice primarily due to the enhanced survival of antigen-experienced T cells...
- Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results
Annemieke Dols
Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213, USA
Hum Gene Ther 14:1117-23. 2003
..This immunization strategy proved to be safe and feasible, and induced tumor-specific immune responses in a minority of patients; however, no objective tumor regressions were observed...
- Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization
Edwin B Walker
Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
Clin Cancer Res 14:5270-83. 2008
..We sought to characterize the phenotype and function of gp100 peptide-specific memory CD8+ T cells in melanoma patients after primary gp100(209-2M) immunization and assess the anamnestic response to boosting immunization...
- Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing
Li-xin Wang
Laboratory of Cancer Immunobiology, Providence Portland Medical Center, Portland, Oregon 97213, USA
Cancer Res 65:10569-77. 2005
....
- Immunological monitoring of patients with melanoma after peptide vaccination using soluble peptide/HLA-A2 dimer complexes
Hong Ming Hu
Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
J Immunother 27:48-59. 2004
..IFN-gamma production by T cells was comparable after stimulation with peptide-pulsed dimers, T2 cells, or autologous dendritic cells. Peptide-loaded A2 dimers could also be used directly to stimulate T cells in the ELISPOT assay...
- Immunotherapy for melanoma: the good, the bad, and the future
Christian H Poehlein
Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, 4805 N.E. Glisan, Portland, OR 97213, USA
Curr Oncol Rep 7:383-92. 2005
..Although this strategy is extremely challenging, one can expect technological advances that may simplify this approach and further improve outcome...
- Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine
Sybren L Meijer
Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR, USA
Cell Immunol 227:93-102. 2004
..Since a tumor-specific type 1 cytokine profile appears critical for mediating anti-tumor activity in vivo, this approach might be used to isolate T cells for adoptive immunotherapy...
- Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood
Edwin B Walker
Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
Clin Cancer Res 15:2541-51. 2009
..The aim of this study was to characterize the primary gp100(209-2M)-specific T-cell response in vaccine-draining, metastases-free lymph nodes and peripheral blood of peptide-vaccinated stage I to III melanoma patients...
- Regression of a mammary adenocarcinoma in STAT6-/- mice is dependent on the presence of STAT6-reactive T cells
Shawn M Jensen
Laboratory of Molecular and Tumor Immunology, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, 4805 NE Glisan Street, Portland, OR 97213, USA
J Immunol 170:2014-21. 2003
..Additionally, these data emphasize that the enhanced ability to mount a type 1-polarized immune response is inconsequential if a sufficient antitumor immune response is not primed by the tumor...
- Signaling through OX40 enhances antitumor immunity
Shawn M Jensen
Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center, Portland, OR 97213, USA
Semin Oncol 37:524-32. 2010
..Combining strategies that prime tumor-specific T cells together with OX40 signaling could generate and maintain a therapeutic antitumor immune response...
- Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses
John W Smith
Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Providence Portland Medical Center, 4805 NE Glisan St, 5F40, Portland, OR 97213 2967, USA
J Clin Oncol 21:1562-73. 2003
..To measure the CD8+ T-cell response to a melanoma peptide vaccine and to compare an every-2-weeks with an every-3-weeks vaccination schedule...
- Regression of bone metastases following adoptive transfer of anti-CD3-activated and IL-2-expanded tumor vaccine draining lymph node cells
Dominik Ruttinger
Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
Clin Exp Metastasis 21:305-12. 2004
..Considering the promising early findings in the present study, further studies exploring the therapeutic potential of adoptive immunotherapy for metastatic disease to the skeleton are warranted...
- Polychromatic flow cytometry: a rapid method for the reduction and analysis of complex multiparameter data
Ulf Petrausch
Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center and Providence Portland Medical Center, Portland, Oregon 97213, USA
Cytometry A 69:1162-73. 2006
..This approach to data analysis may enhance the use of polychromatic flow cytometry for both research and clinical applications...
- Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells
Annemieke Dols
Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, USA
J Immunother 26:163-70. 2003
....
- Allogeneic breast cancer cell vaccines
Annemieke Dols
Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, OR 97213, USA
Clin Breast Cancer 3:S173-80. 2003
..Allogeneic tumor cell vaccines are safe, feasible, and associated with low toxicity, and the early clinical results suggest that they are worthy of further study..
- Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy
Yuhuan Li
Laboratory of Cancer Immunobiology, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
Clin Cancer Res 17:7047-57. 2011
....
- Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies
Hauke Winter
Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR, USA
Immunology 108:409-19. 2003
..These results provide insights into the development of a protective anti-tumour immune response and strengthen the hypothesis that a T1 cytokine response is critical for T-cell-mediated tumour regression...
- Multiple vaccinations: friend or foe
Sarah E Church
Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Cancer Center, Portland Medical Center, USA
Cancer J 17:379-96. 2011
....
- Science gone translational: the OX40 agonist story
Andrew D Weinberg
Providence Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213, USA
Immunol Rev 244:218-31. 2011
..This review describes the journey from in vitro experiments through preclinical mouse models to the successful translation of the first OX40 agonist to the clinic for the treatment of patients with cancer...
- Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma
John W Smith II
Robert W. Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Oregon, USA
J Immunother (1997) 26:130-8. 2003
....
- Cross-presentation of tumor associated antigens through tumor-derived autophagosomes
Yuhuan Li
Laboratory of Cancer Immunobiology, Providence Portland Medical Center, 4805 N E Glisan Street, Portland, OR 97213, USA
Autophagy 5:576-7. 2009
..The exact nature or form of the antigens derived from donor cells at the time of delivery to the APC for cross-presentation is very controversial...
- Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution
Jun Ma
Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, USA
Eur J Immunol 33:2123-32. 2003
....
- Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects
Ulf Petrausch
Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, 4805 NE Glisan Street, Portland, OR 97213, USA
Curr Mol Med 9:673-82. 2009
..Finally, we will describe possible ways to interfere with regulatory T cell-mediated immune suppression with the focus on recent pre-clinical and clinical findings...
- Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study
Andrew D Weinberg
Earle A Chiles Research Institute, Robert W Franz Cancer Center, Providence Portland Medical Center, 5F40, Portland, OR 97213, USA
J Immunother 29:575-85. 2006
..These studies demonstrate the immune-stimulatory properties and safety of anti-OX40 in primates and provide a strong scientific rationale to pursue clinical trials in humans...
- Efficient cross-presentation depends on autophagy in tumor cells
Yuhuan Li
Laboratory of Cancer Immunobiology, Providence Portland Medical Center, OR 97213 2967, USA
Cancer Res 68:6889-95. 2008
....
- Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses
Steven K Seung
Earle A Chiles Research Institute, Portland, OR 97213, USA
Sci Transl Med 4:137ra74. 2012
....
- Integrating new therapies in the treatment of advanced melanoma
Brendan D Curti
Providence Cancer Center, Portland, OR 97213, USA
Curr Treat Options Oncol 13:327-39. 2012
..Selected patients can benefit from surgical resection or radiation to manage oligometastatic disease...
- Undefined-antigen vaccines
Hong-Ming Hu
Laboratory of Cancer Immunobiology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, USA
Cancer Treat Res 123:207-25. 2005
....
- Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain
Nicholas P Morris
Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, 4805 N E Glisan Street, Portland, OR 97213, USA
Mol Immunol 44:3112-21. 2007
..Our ultimate goal is to use this recombinant molecule in a future clinical trial, and we feel that the OX40L hexamer will have equivalent or superior agonist activity in vivo when compared to an anti-OX40 antibody...
- TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells
Christian H Poehlein
Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, 4805 NE Glisan Street, Portland, OR 97213, USA
J Immunol 170:2004-13. 2003
..These insights could be used to monitor and potentially tune the immune response to cancer vaccines...
- CD28, TNF receptor, and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells
Hong Ming Hu
Laboratory of Molecular and Tumor Immunology, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Cancer Center and Providence Portland Medical Center, OR 97213, USA
J Immunol 169:4897-904. 2002
..Thus, cross-priming of therapeutic CD8(+) T cells by a tumor vaccine transduced with GM-CSF requires TNFR, IL-12, and CD28 signaling...
- Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells
Sybren L Meijer
Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute, Providence Portland Medical Center, Oregon 09713, USA
J Immunother (1997) 25:359-72. 2002
..No objective tumor regressions were observed. MHC class I restricted, tumor-specific cytokine secretion was observed in lymphocytes from TVDLN and the peripheral blood of vaccinated patients...
- Development of antitumor immune responses in reconstituted lymphopenic hosts
Hong Ming Hu
Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
Cancer Res 62:3914-9. 2002
..Vaccination is best performed concomitantly with reconstitution; delayed vaccination resulted in T cells with less therapeutic activity...
- Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer
Eric J Small
University of California, San Francisco, Comprehensive Cancer Center, San Francisco, California 94115, USA
Clin Cancer Res 13:3883-91. 2007
..The immunotherapy, based on the GVAX platform, is a combination of two prostate carcinoma cell lines modified with the granulocyte macrophage colony-stimulating factor (GM-CSF) gene...
- Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
David F McDermott
Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, E KS 153, Boston, MA 02215, USA
J Clin Oncol 23:133-41. 2005
..The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma...
- Are all hypotheses generated before data analysis prospective?
Walter J Urba
J Clin Oncol 20:1431-3. 2002
- Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma
Jeffrey A Sosman
Vanderbilt Ingram Cancer Center Vanderbilt, University Medical Center, Section of Hematology Oncology, 777 Preston Research Bldg, Nashville, TN 37232 6307, USA
J Clin Oncol 26:2292-8. 2008
..We evaluated 210M with one of three different IL-2 schedules to determine whether a basis exists for a phase III trial...
